Could Buying RKLB Before the SpaceX IPO Set You Up for Life?

SpaceX is reportedly targeting a $2 trillion IPO valuation, or 107x last year's sales, while posting a $4.3 billion net loss in Q1 2026 on $4.7 billion of revenue after integrating xAI, which posted a $6.4 billion operating loss in 2025. The article argues Rocket Lab is a more attractive alternative, citing 38% 2025 revenue growth to $602 million and expectations for EBITDA profitability in 2027 and GAAP profitability in 2028. Overall tone is skeptical on SpaceX's IPO and relatively constructive on Rocket Lab, though the piece is opinion-driven rather than event-driven.

Analysis

The market is likely treating the SpaceX IPO as a pure scarcity event, but the more important signal is capital intensity leaking into equity returns. When a high-growth platform needs to fund multiple loss-making vectors at once, the IPO becomes less about growth optionality and more about balance-sheet repair; that usually compresses the post-listing multiple once the first lockup and quarterly print force investors to separate narrative from unit economics. The retail-heavy allocation is also a tell: it broadens distribution, but it can worsen initial price discovery if early demand is momentum-driven rather than fundamental.

Rocket Lab’s relative setup is stronger because it offers the same broad thematic exposure without the embedded cross-subsidy risk from adjacent businesses. The key second-order effect is that a successful SpaceX debut could actually lift the whole space basket in the short run, but the better-funded, simpler names should outperform once investors start benchmark-testing valuation against growth, backlog quality, and gross margin trajectory. In that regime, companies with government exposure and nearer-term path to operating leverage tend to outperform because they are easier to underwrite on 12-24 month horizons.

The main contrarian risk is that the current enthusiasm for private-space and AI may remain dominant long enough to keep valuation discipline irrelevant for several quarters. If SpaceX lists with strong retail demand and a clean first trade, it can reinforce speculative flows into adjacent names like Rocket Lab, BlackSky, and even broader exchange and market-data infrastructure exposure through higher issuance and trading activity. But if the first two reporting periods reveal that growth is being purchased with perpetually expanding losses, the multiple gap should widen in favor of the cleaner balance-sheet names rather than narrow.

Key Decisions for Investors

• Long RKLB vs. short a space-themed basket into the IPO window; target 1-3 months. Thesis: Rocket Lab should benefit from thematic spillover but with lower execution risk and a cleaner path to margin expansion; stop if RKLB rerates >15% on pure momentum without fundamental revisions.
• Buy RKLB call spreads 3-6 months out on any post-IPO pullback. Preferred structure: limited premium outlay to capture a thematic re-rating while capping downside if the market stops rewarding space exposure.
• Avoid chasing the SpaceX IPO on day one; wait for first earnings and lockup dynamics. If the stock trades above an extreme revenue multiple and the first quarter shows continued loss amplification, the risk/reward turns decisively unfavorable over the following 1-2 quarters.
• Add BKSY only on weakness as a high-beta sentiment proxy, not a core fundamental long. Timeframe: tactical 2-8 weeks. It can squeeze with the sector, but it is the first name likely to give back gains if the market rotates from narrative to profitability.
• Use SDA as a lower-volatility beneficiary of the same government-space spend cycle. Over 6-12 months, SDA exposure is better suited to a basket approach because procurement visibility can offset some of the multiple compression risk seen in the pure high-growth names.